File(s) not publicly available
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
journal contribution
posted on 2023-06-08, 10:43 authored by Mike Youle, Schlomo Staszweski, Bonaventura Clotet, Martin Fisher, José Ramon Arribas, Anders Blaxhult, Giampiero Carosi, Edwin DeJesus, Gianni Di Perri, Vincente Estrada, Colin Kovacs, Ranjababu Kulasegaram, othersRecent data from clinical trials investigating the efficacy of enfuvirtide, a fusion inhibitor, in treatment-experienced patients have revealed that the addition of enfuvirtide (ENF) to an active boosted protease inhibitor regimen doubles the rate of virological response. At week 48 of the TORO studies, 55% of patients previously naive to and receiving lopinavir/ritonavir (LPV/r) with ENF achieved a viral load of <400 copies/mL compared with 24% of patients treated with LPV/r alone. At week 24 of the RESIST studies, 70% of previously ENF-naive patients who took both ENF and tipranavir/ritonavir (TPV/r) achieved a =1 log10 reduction in viral load compared with 37% of such patients treated with TPV/r alone. Similarly, concomitant use of TMC114/ritonavir (TMC114/r) with ENF, compared with TMC114/r alone, increased the number of patients with <50 copies/mL from 46% to 64% in a combined 24-week analysis from the POWER trials. Data from these trials suggest that combining one agent from a new class with a new agent from a previously exposed class offers a greater chance of achieving full virological control than either type of agent alone. Undetectable viraemia should be the primary objective for treatment-experienced patients requiring a switch in therapy, and the present data support the combination of an active boosted protease inhibitor with an agent from a new class (e.g., ENF) for triple-class-experienced patients.
History
Publication status
- Published
Journal
HIV Clinical TrialsISSN
1528-4336Publisher
Taylor & FrancisExternal DOI
Issue
2Volume
7Page range
86-96Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-02-21Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC